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Abstract
Diabetes mellitus (DM) is a disease characterized by defects in action and/or 
secretion of insulin that results in chronic hyperglycemia and long-term severe vas-
cular complications. The main clinical presentations with the proven genetic base 
are covered. Type 1 diabetes (DM1) is an autoimmune, heterogeneous, multifacto-
rial, and polygenic-based disease. Selectively destroys 90% of beta cells of the pan-
creas, mediated by activated T lymphocytes in patients with haplotypes linked to 
major histocompatibility complex (MHC). Genetic and genomic studies have been 
carried out in family groups, demonstrating up to 15 affected chromosomal regions. 
Type 2 diabetes (DM2) presents genes with various polymorphisms which, together 
with post-genomic and environmental factors, make it more complex to understand 
the pathogenesis. Monogenic diabetes comprises neonatal diabetes (ND), maturity 
onset diabetes in young (MODY), an autosomal dominant transmission which is 
inherited directly in three successive generations, and the very rare mitochondrial 
diabetes. Latent autoimmune diabetes in adults (LADA) mainly affects patients 
with normal weight and initially diagnosed as DM2. Its characteristics are low levels 
of C-peptide in both fasting and post-glucagon tests. They present MHC alleles of 
susceptibility and positive autoantibodies: Anti-decarboxylase glutamic acid.
Keywords: diabetes mellitus type 1, diabetes mellitus type 2, monogenic diabetes, 
LADA
1. Introduction
Diabetes mellitus (DM) is a group of metabolic diseases of different etiologies 
characterized by chronic hyperglycemia resulting from a deficit in both the secre-
tion and the action of insulin hormone. Now-a-days, there is a genetic basis of these 
clinical manifestations. In this chapter, we describe the most important ones such 
as diabetes mellitus type 1 (DM1), diabetes mellitus type 2 (DM2), monogenic 
diabetes, and latent autoimmune diabetes in adults (LADA).
2. Diabetes mellitus type 1
DM1 is characterized by autoimmune destruction of the beta cells of the pancre-
atic islets, which leads to an extreme insulinopenia. The character of autoimmunity 
confirm the presence of islet cell antibodies (ICA), insulin auto antibodies (IAA), 
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glutamic acid decarboxylase auto antibodies (GAD65), protein tyrosine phospha-
tase 2 (IA-2), and zinc transporter gene ZnT8 [1]. There is an interaction between 
genetic and environmental factors in the development of DM1 (Figure 1).
2.1 Genetic factors of DM1
DM1 is a polygenic disease, with at least 15 associated chromosomal regions. The 
leading group of genes that predispose to type 1 diabetes is located on human chro-
mosome 6 specifically at 6p21, and this chromosomal region contains a group of 
genes called major histocompatibility complex (MHC), responsible for the immune 
response and the antigen presentation of the beta cell to T lymphocytes [2]. The 
classic histocompatibility genes are extremely polymorphic (amino acid sequence 
differs among individuals) and include MHC-A, B, and C molecules (class I his-
tocompatibility antigens) and the immune-response genes DP, DQ , and DR (class 
II histocompatibility antigens). Numbers (DR3, DR4; A1, A2; B1, B8) are given to 
distinguish different alleles of any given gene. The designation w (workshop) with 
numbers is given for provisionally named alleles (DQw8, DQw7) [3]. DM1 has been 
associated mainly with allelic variants of MHC-DR (DR3/DR4). The MHC locus is a 
genetic factor of great importance in DM1, and it was first shown in an association 
study that revealed that about 95% of all patients with DM1 were heterozygous for 
MHC-DR3/DR4. The majority of type 1 diabetics have the MHC-DR3, MHC-DR4 
haplotype, or both [4]. Susceptibility to DM type 1 is associated with these linked 
DQ alleles that are often in linkage disequilibrium with DR. The closest associa-
tion in DM1 occurs with the haplotypes DQA1*0301, DQB1*0302, DQA1*501, and 
DQB1*0201. It has been shown that the beta DQ chains of those affected have 
valine, alanine, or serine at position 57; near the peptide-binding gap, presence 
of aspartic acid is normal [5] Factors involved in the pathophysiology of DM1 are 
shown in (Figures 2 and 3).
However, there are exceptions to this association, which indicates that amino 
acids other than Asp57 at position 57 of the beta chain play an essential but not 
exclusive role in the susceptibility to DM1 [5]. There is an interaction between 
genetic and environmental factors in the development of DM1.
2.2 Heritage in type 1 DM
The inheritance of DM1 is unknown. Several hypotheses have been suggested, 
such as that of dominant inheritance, but it is ruled out by the rarity of DM1 in 
relatives, children, and descendants. The possibility of recessive inheritance was also 
Figure 1. 
Pathogenesis of type 1 diabetes.
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considered, however, invalidated because in homozygotes for the DR3 or DR4 alleles, 
the susceptibility to the disease is not increased. The observation that heterozygosis 
DR3/DR4 increases the risk for diabetes, compared with that presented by homo-
zygotes from other high-risk alleles, suggests a polygenic way of inheritance. The 
diabetogenic MHC haplotype is necessary for the susceptibility to DM1, but must 
be positively or negatively influenced by genes not linked to MHC, such as the gene 
located close to the repeated DNA sequence minisatellite, in the promoter region 
of the gene of the insulin (chromosome 11p15); one gene on chromosome 11q and 
another on chromosome 6q [6]. Some genes seem to confer protection against the 
development of the disease. For example, the DQA1*0102 and DQB1*0602 haplotypes 
are present in 20% of the United States population but is extremely rare in individuals 
with DM1 (<1%). This situation indicates that several genes are interacting to deter-
mine the DM1 phenotype, so this disease presents genetic heterogeneity (Figure 4).
DM1 is uncommon in Chile and usually does not occur in native Chilean 
families. A study of a family with an affected female child was carried out in a 
Mapuche community in the Southern (VIII region). This case is a unique and 
sporadic DM1 case with Mapuche heritage. Genetic analysis by PCR was done 
Figure 2. 
Etiology of type 1 diabetes. MHC-DQ B antigen amino acid sequence.
Figure 3. 
Pathophysiology of type 1 diabetes.
Metabolic Disorders
4
to detect class I and II HLA genes by reverse dot blot. The proband, her mother, 
and sister had positive islet cell antibodies (ICA). Her father and brother were 
negative. All the family was positive for anti-glutamic decarboxylase antibodies 
(GAD65). All subjects had HLA-DRB1 0407/0407 and HLA-DQB1 0302/0302 
alleles. The index case and her father were homozygotes for the HLA-A1: 
A*68012/A*68012 allele. No evidence of viral infections such as rubella, mumps, 
or measles was found in this family. All genotypes were compared with the 
European population, where the diabetogenic combination DR4/DQB1*0302 is 
the most prevalent [5]. Finally, despite of the high relative risk of DM1 in subjects 
with certain MHC class II alleles, it does not develop in the majority of people 
who inherit these alleles, which also suggests that environmental factors influence 
development of the disease [1] (Figure 4).
2.3 Clinical manifestations of type 1 diabetes
The onset of DM1 is usually abrupt, with severe symptoms attributable to 
hyperglycemia maintained for days or weeks, such as polyuria, polydipsia, 
polyphagia, asthenia, and progressive weight loss, and manifests as diabetic 
ketoacidosis. Two pathophysiological situations must be present to establish this 
condition: extreme insulinopenia and increase of counterregulatory hormones, 
principally glucagon. DM1 is observed mainly in children, adolescents, and young 
adults, generally under 30 years, although it can also appear in individuals of more 
advanced ages.
3. Diabetes mellitus type 2
DM2 has an important genetic component in its pathogenesis. There are multiple 
genes involved in different metabolic pathways that contribute to the pathogenesis 
of the disease, in addition to environmental factors such as obesity, an unhealthy 
diet, and a sedentary lifestyle. These genes have various polymorphisms, which 
added to post-genomic factors related to their expression and inhibition are respon-
sible for this complex disease, as seen in Figure 5.
3.1 Heritage in type 2 diabetes
The genetic nature of DM2 has been based on high heritability, estimated at 
30–70% and high prevalence in some ethnic groups; 39% of patients with DM2 have 
at least one relative with the disease. There are 1.5–3 times higher risk of presenting 
Figure 4. 
Interaction of genetic and environmental factors about the immune response in type 1 diabetes.
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DM2 if there is a history of the disease in the family; if the affected one is the 
mother or the brother, the risk is of 2 and 3 times greater, respectively. The herita-
bility described is mainly in middle-aged people (35–60 years) decreasing markedly 
in larger groups [6]. First-degree relatives of people with DM2 show early defects 
in insulin withdrawal and action [7]. If other factors such as obesity and impaired 
fasting glycemia are added to the family history, the risk of presenting the disease 
is 16 times higher. The presentation of DM2 involves genes that code for proteins or 
related enzymes in the process of pancreatic formation, synthesis, sectioning, and 
insulin action. Genome-wide association studies (GWAS) have shown more than 
100 locus susceptible to DM2, most related to insulin sequestration, suggesting that 
this alteration, essential for the presentation of the disease, is more strongly deter-
mined by genetic factors.
The genetic susceptibility given by the presence of risk variants is responsible for 
about 10% of the family aggregation of the disease. There is a considerable percent-
age of “missing heritability” that could be explained by: frequent variants of low 
power, others of low frequency but powerful effect, interaction between gene–gene, 
gene–environment interaction, epigenetic factors, and others.
3.2 Genetic defects in the action of insulin
The genetic variants associated with the action of insulin and DM2 are related 
to the transcription of the intracellular signal of insulin. Due directly to protein 
mutations of the signaling cascade intracellularly or indirectly due to mutations in 
genes associated with metabolic syndrome, such as those related to obesity and lipid 
metabolism. Yaghootkar et al. evolved cluster of 17 genetic variables associated with 
insulin resistance related to the development of DM2 [8]. Some of the genes that are 
most related to DM2 appear in Table 1 [9].
3.2.1 Insulin receptor substrate-1 gene (IRS-1)
Located on chromosome 2, it encodes peptides related to the insulin signaling 
cascade. Arg972Gly mutation, a common variant of IRS-1, is more prevalent in 
Caucasian DM2 than in non DM2, and in obese adults, it has been associated with 
increased insulin resistance.
Figure 5. 
Pathogenesis of type 2 diabetes.
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3.2.2 Peroxisome proliferator-activated receptor gamma 2 gene (PPARG)
Located on chromosome 3, it codes for the peroxisome proliferator-activated 
receptor. It has a key role in adipocyte differentiation. The presence of a type of 
polymorphism is associated with 1.25 odds ratio (OR) for DM2.
3.2.3 Protein tyrosine phosphatase receptor type D gene (PTPRD)
Located on chromosome 9, it is encoded for PTPRD. Its overexpression in the 
skeletal muscle generates insulin resistance. Diabetes-related polymorphism has 
been evidenced in Chinese with an OR 1.57.
3.2.4 β-3 adrenergic receptor gene
It regulates lipolysis of visceral fat and is related to thermogenesis. It is associ-
ated with risk of obesity and early presentation of DM2.
3.2.5 Adiponectin gene
It is located in chromosome 3q27. Low levels of adiponectin have a role in the 
pathogenesis of insulin resistance and obesity. Insulinosensitivity is a consistent and 
independent predictor factor of DM2. Variants in the genes that code for adiponec-
tin receptor have proven to be a risk factor for presenting DM2 in some populations.
3.2.6 Leptin gene
Mutations related to this gene are involved with the pathogenesis of obesity 
and glucose metabolism, thereby decreasing insulin sensitivity and inhibiting the 
expression of the pre-proinsulin gene in the pancreatic β-cells. Recent evidence 
suggests that high circulating levels of leptin probably independent of adiposity are 
associated with an increased risk of type 2 diabetes in men.
3.3 Genetic defects in insulin secretion
There are multiple loci associated with this defect that have been found in 
GWAS studies. Among them most relevant are those presented in Table 2 [9].
3.3.1 Calpain 10 gene (CAPN10)
Encodes a family of calpain enzymes, it was one of the first to study in linkage, 
but it is currently known that the risk of this association is low OR 1.17 [10].
Insulin resistance genes
• Insulin receptor substrate gene-1 (IRS-1)
• Peroxisome proliferator-activating receptor gene (PPARΎ)
• Protein tyrosine phosphatase receptor type D (PTPRD)




Candidate genes of DM2 for insulin resistance.
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3.3.2 Transcription factor 7-like 2 gene (TCF7L2)
It has appeared to be more relevant in the genetic susceptibility to DM2, since 
a polymorphism of this gene has been found in several ethnic groups of DM2 
patients. The increased expression of the gene in the pancreatic beta cell causes 
secretion alteration due to a decrease in the incretin effect. In liver and adipose 
tissue, it generates insulin resistance. The risk of DM is consistent with an OR up to 
2.5 for homozygous variable [11].
3.3.3 Potassium voltage-gated channel subfamily
Q member 1 (KCNQ1) located on chromosome 11, it codes for the same name 
channel present in the cell membrane. There are four variants associated with 
DM2 in various populations. Studies suggest that the effect linked to DM2 is related 
to epigenetic modifications. J Member 11 (KCNJ11): code for Kir6.2 ATP-sensitive 
potassium channel. Variant E23K increases the risk of DM2 by 1.2 times associated 
with decreased insulin sequestration [12].
3.4 Epigenetics in DM2
Epigenetics or genetic modifications not associated to nucleotide mutations 
that influence the expression of a gene play a key role in the pathogenesis and 
T2DM complications. There are prenatal factors that induce epigenetic changes 
that increase the risk of T2DM by altering the secretion and sensitivity of insulin, 
hepatic glucose production, and the release of hormones involved in glucose 
metabolism.
The sustained activation of inflammatory-related genes in T2DM patients by 
epigenetic mechanisms contribute to the progression of vascular complications, 
arteriosclerosis, and retinopathy.
Types of epigenetic modifications and relation to DM2 are shown in Figure 6.
3.4.1 Methylation and histone-modification
These are the epigenetic modifications most associated to vascular complications 
related to DM2. Both hypomethylations and hypermethylations generate persistent 
activation of proaterogenic genes such as NF-kB-dependent oxidative and inflam-
matory signaling pathway.
3.4.2 Non-coding RNAs (ncRNAs) and chromatin remodeling
Non-coding nRNAs play an essential role in post-transcriptional regulation of 
gene expression.
Insulin secretion genes
• Calpain 10 gene (CAPN10)
• Transcription factor 7-like 2 (TCF7L2)
• Potassium voltage gated channel subfamily
• Q member 1 (KCNQ1)
• J member 11 (KCNJ11)
Table 2. 
Candidate genes of DM2 for insulin secretion.
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The most extensively studied are short nucleotide sequences (18–25) called 
MicroRNA (miRNA) and represent the principal epigenetic regulators of gene 
expression.
Deregulation in epithelial cells is correlated to the risk of developing vascular 
complications in DM2.
There are miRNAs associated with inflammation; for example, miR-155, which 
is associated to the progression of kidney disease in DM2 patients and miR-126, that 
when inhibited in pre-diabetes patients is correlated with the increase of activation 
of the NF-kb pathway in endothelial cells.
Long non-coding RNAs (lncRNAs) have been associated with pancreatic B cell 
damage, increase of inflammatory processes, alterations in the immune response, 
and insulin resistance in TSDM. Chromatin remodeling that regulates gene expres-
sion, such as p66Shc, has been linked with insulin resistance, increase of vascular 
risk in DM2, and obesity [13].
DM2 is a polygenic disease, of high heritability, which involves genes related to 
insulin and action, in addition to those that code for the components of the meta-
bolic syndrome. What has been discovered so far is broad but only accounts for a 
part of the complex relationship of genetics and its phenotypic expression in DM2. 
The study of epigenetics in DM2 has opened the possibility to find pathogenetic 
markers at the onset of the disease and during the development of chronic compli-
cations, which will allow early screening and individualized treatment in the near 
future.
4. Monogenic diabetes
It is caused by one or more defects in a single gene. The disease can be inherited 
within a family by the genetic transmission of a dominant or recessive nature and 
not Mendelian. It can also be presented as a spontaneous case due to a de novo 
mutation [14]. Monogenic diabetes includes neonatal diabetes, maturity onset 
diabetes young (MODY), and mitochondrial diabetes (Figure 7).
4.1 Neonatal diabetes
It is defined as diabetes that appears before 6 months of age and is subdi-
vided into transitory (TNDM) and permanent (PNDM). TNDM develops in the 
first weeks of life and resolves within a few months, but 50% have a relapse in 
adolescence or adulthood. TNDM is most frequently caused by abnormalities 
Figure 6. 
DM2 epigenetic factors.
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in the imprinted region of chromosome 6q24 (spanning two candidate genes 
PLAGL1 and HYMAI), thereby leading to overexpression of paternally derived 
genes. Activating mutations in either the KCNJ11 or ABCC8 genes encoding the 
two subunits (Kir6.2 and SUR1, respectively) of the adenosine triphosphate-
sensitive potassium channel on the beta-cell membrane prevent insulin secretion 
in response to hyperglycemia and can cause both PNDM and TNDM. Diabetes 
caused by mutations in KCNJ11 and ABCC8 often responds to sulfonylureas. 
Mutations in other genes critical to beta-cell function and regulation, and in the 
insulin gene itself, also cause PNDM. Heterozygous coding mutations in the pre-
proinsulin gene (INS) are the second common cause of PNDM after KATP channel 
mutations [15, 16].
4.2 MODY
Described in 1975 by Tattersall and named in 1976 by Fajans, MODY is rec-
ognized as a form of mild-presenting family diabetes that is diagnosed during 
adolescence or early adulthood. Currently, other types are identified with a less 
classic presentation [4, 5]. It is estimated that its prevalence is underestimated, and 
it would correspond about 5% of DM2 and a similar percentage in DM1.
It is presented in 3.6% of the population with diabetes under 30 years [4]. 
MODY is a heterogeneous group of disorders caused by mutations in genes 
essential for beta-cell development, function and regulation, glucose sens-
ing, and in the insulin gene itself. Although at least 14 genes are associated 
with MODY, we describe the four most frequent types (Table 3). Mutations in 
HNF-1α, HNF-4α, HNF-1β, and GCK genes account for over 80% of all known 
MODY cases.
Heterozygous mutations in three of them are responsible for the majority of 
cases of this type of diabetes: glucokinase gene (GCK); two genes encoding hepato-
cyte nuclear factor (HNF) transcription factors HNF-1α and HNF-4α. Most MODY-
causative genes, except GCK, encode transcription factors expressed in pancreatic 
beta-cells (Table 4). The majority of patients with MODY exhibit isolated diabetes 
or stable mild fasting hyperglycemia, but some MODY subtypes have additional 
features, such as renal abnormalities (MODY 5) and pancreatic exocrine dysfunc-
tion (MODY 6) [17–20].
4.2.1 MODY 2 (GCK)
GCK, a glucose sensor expressed in pancreatic beta-cells, is a key enzyme in 
glucose metabolism that catalyzes the conversion of glucose to glucose-6-phosphate 
and thus controls glucose-mediated insulin secretion. As such, GCK serves to facili-
tate insulin release that is both appropriate and proportional to the blood glucose 
concentration. Heterozygous inactivating mutations in GCK (MODY 2) increase 
the set point for insulin secretion in response to increased blood sugar, thereby 
causing stable, mild fasting hyperglycemia. More than 600 mutations have been 
Figure 7. 
Subtypes of monogenic diabetes.
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reported. Patients with MODY 2 are usually asymptomatic, and they do not require 
treatment. In pregnancy, insulin may be required to prevent fetal complications, 
such as high birth weight and neonatal hypoglycemia. These neonatal complications 
are dependent on whether the mutation is inherited.
In 2018, a MODY family study was published in Chile [21]. The case is about a 
17-year-old woman with DM, fasting blood glucose 130 mg/dl, without ketosis or 
weight loss, and BMI 18 kg/m2. No signs of insulin resistance were seen, C-peptide 
2.3 ng/ml (normal) and negative DM1 autoantibodies. In a family study, diabetic 
father and brother with impaired fasting blood glucose (Figure 8). The genetic-
molecular analysis of the GKC gene, the patient, the father, and the brother 
presented a mutation at position 1343 of exon 10 corresponding to a heterozygous 
exchange of guanine for adenine (1343 G > A). The change is not synonymous 
and determines that at position 448 of the GKC enzyme, the amino acid glycine 
is substituted by aspartic acid. Diagnosis of MODY 2 was confirmed, and it was 
established that the mutation was by paternal line.
4.2.2 MODY 3 (HNF-1α)
The transcription factor HNF-1α is expressed in the liver, kidney, intes-
tine, and pancreatic beta-cells. Heterozygous HNF-1α mutations result in 
progressive beta-cell dysfunction that leads to diabetes in early adult life. 
MODY 
subtypes




Hyperglycemia Other clinical features Possible treatment






2 10 (0–18) Mild Mild fasting long-term 
stability asymptomatic
Diet no medication
3 |4 (4–18) High Glycosuria—very low 




5 <25 Variable Renal malformations, genital 
anomalies, pancreatic 
hypoplasia, low birth weight
Insulin
Table 4. 
Clinical characteristics of most common MODY subtypes.
Gene Frequency % Physiopathology
MODY 2 GCK 15–20 Glucose sensing defect
MODY 3 HNF-1α 30–50 Insulin secretion deficit
MODY 1 HNF-4α 5 Insulin secretion deficit
MODY 5 HNF-1β 5 Beta cell dysfunction
GCK, glucokinase; HNF, hepatocyte nuclear factor.
Table 3. 
Frequent types of MODY and its pathophysiological alteration.
11
Diabetes Mellitus: A Group of Genetic-Based Metabolic Diseases
DOI: http://dx.doi.org/10.5772/intechopen.89924
According to studies, a total of 414 different HNF-1α mutations were identified 
in 1200 families, where a mutation (P291fsinsC) in exon 4 was the most common. 
Hyperglycemia associated with MODY 3 may be severe, and the risk of micro-
vascular and macrovascular complications is similar to DM1 and DM2. Because 
of this, patients require strict glycemic control and close monitoring of possible 
complications. There is a defect in the renal resorption of glucose, characterized 
by a decreased glucose threshold for glycosuria and reduced tubular reabsorption 
of glucose. Patients are sensitive to sulfonylurea therapy, but most of them even-
tually progress to insulin treatment. This subtype of MODY is the most frequent 
in Europe and the US.
4.2.3 MODY 1 (HNF-4α)
This MODY was the first described. The transcription factor HNF-4α is 
expressed in the liver, kidney, and pancreatic beta-cells. HNF-4α gene encodes 
a transcription factor important for pancreatic development and beta-cell dif-
ferentiation and function. Heterozygous HNF-4α mutations cause a similar 
clinical phenotype observed in MODY 3. Most patients have a progressive insulin 
deficiency, diabetes onset before age 25 years, and a response to relative low-dose 
sulfonylurea therapy. Fetal HNF-4α heterozygosity results in macrosomia due to 
hyperinsulinemia in utero and subsequent neonatal hyperinsulinemic hypogly-
cemia, which is responsive to diazoxide. MODY 1 is associated with triglyceride 
metabolism, and mutation carriers may exhibit reduced levels of apoproteins 
(apoAII, apoCIII, and apoB).
4.2.4 MODY 5 (HNF-1β)
The transcription factor HNF-1β is involved in the organogenesis of the kidney, 
genitourinary tract, liver, lungs, gut, and pancreas. Patients with heterozygous 
Figure 8. 
Chilean family inheritance pattern MODY 2.
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mutations in HNF-1β rarely present with isolated diabetes. By contrast, patients 
usually have renal disorders (especially renal cyst and renal dysplasia). Urogenital 
tract abnormalities and atrophy of pancreas may also occur. The sensitivity to sul-
phonylureas is absent, and early insulin therapy is required. At least 50% of HNF-1β 
MODY cases are due to microdeletion of chromosome 17 (17q12) involving between 
15 and 29 genes, including HNF1β. De novo mutations are frequent (up to 50% of 
cases) and hence family may be absent.
4.3 Mitochondrial diabetes
This disease is a mitochondrial disorder characterized by maternally transmit-
ted diabetes and sensorineural deafness. The most common form is caused by an 
exchange between an adenine for guanine (3243A/G) in DNA. This mutation also 
causes a severe neuromuscular disease syndrome called MELAS (mitochondrial 
myopathy, encephalopathy, lactic acidosis, and stroke). Diabetes onset is usu-
ally insidious, but 20% of patients have an acute presentation, even in diabetic 
ketoacidosis. It usually occurs in the third to fourth decades of life in non-obese 
individuals [14].
5. Diagnostic algorithm of diabetes in young adult
Figure 9 shows a diagnostic algorithm for diabetes in patients under  
30 years of age.
Figure 9. 
Diagnostic algorithm of diabetes in young adult.
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6. LADA: Latent autoimmune diabetes adult
Diabetes is a complex disease, which makes its classification difficult. DM1 
is caused by autoimmune destruction of the beta cell, which leads to absolute 
insulin deficiency. DM2 is secondary to the progressive loss of insulin secretion 
by the beta cell, in the context of insulin resistance. Other types of diabetes are 
gestational diabetes, MODY, post-transplant, and exocrine, among others [22]. 
DM1 is a heterogeneous disease, the incidence of which is higher in children and 
adolescents, characterized by the presence of specific immunological markers. 
However, no less than a percentage of adults experience the disease; so, the term 
latent adult diabetes (LADA) has been coined. In this case, the disease is even 
more heterogeneous, since there is a variable proportion of destruction of the 
beta cell, with the presence of immunological markers, but zero or deficient 
initial insulin requirements, so they can initially be misclassified as DM2 [23]. 
These patients probably have pathophysiological processes similar to DM1, but 
with differences in genetic penetrance and immune factors. The term LADA was 
introduced in the 90s, to define a subgroup of patients with diabetes initially 
not requiring insulin, but with immunological markers of DM1 detectable in 
the serum [24]. In 2015, the Immunology of Diabetes Society proposed three 
diagnostic criteria for LADA: age of onset>30 years, presence of any DM1 marker 
antibody, and lack of need for insulin treatment for at least 6 months from 
diagnosis [25].
Currently, the American Association of Diabetes (ADA) does not recognize this 
entity, but instead classifies it within the group of patients with DM1, but every day 
there is more information about its clinical and pathophysiological characteristics, 
which keep the debate open.
6.1 Epidemiology
The available data show that the prevalence of LADA is higher than previ-
ously recognized. About 40% of cases of DM1 occur in adults over 30 years [26]. 
Scandinavian studies show that 7.5–10% of the population with apparent DM2 have 
circulating antibodies against the beta cell (ICA or GAD 65) [27]. The Action LADA 
study, conducted in Europe, which evaluated 6000 adults attended in primary and 
secondary care centers, reported a frequency of 9.7% of LADA [28]. A Chinese 
study, LADA China study reported a 5.9% positive antibody in adults previously 
diagnosed with DM2 [29]. The prevalence of LADA is, therefore generally under-
estimated, due to the lack of study with antibodies in adult patients; so, the level of 
clinical suspicion should be high.
6.2 Pathophysiology
6.2.1 Genetics
In genotype analysis, patients with LADA have been shown to share genetic 
characteristics with DM1 (HLA, INS VNTR, CTLA4, and PTPN22) and DM2 
(TCF7L2) [30], which might suggest that LADA is a spectrum of insulin 
deficiency between DM1 and DM2. The HLA-DRB1*04-DQB1*0302 and HLA-
DRB1*0301DQB1*0201 haplotypes, which confer high susceptibility to DM1, 
and decrease progressively with increasing age, have been further diminished 





DM1 is a known autoimmune disease, mediated by cells. The presence of T 
lymphocytes that are reactive to islet cells, in LADA, gives us some evidence that there 
is a cell-mediated immune response as well [32]. Adult autoimmune diabetes has a 
“lower genetic load,” characterized by lower circulating antibodies than early-onset 
DM1 in childhood or adolescence, which correlates with less intense beta cell destruc-
tion and lower HLA genetic susceptibility. Many studies have compared circulating 
antibodies in early DM1 in childhood with LADA, finding ICA, AAI, IA-2, and anti 
ZnT8 more frequently in children than in adults, while anti GAD and IA-2 were found 
with similar frequency in both ages [33]. Anti-GAD is the antibody most frequently 
found in patients with LADA, up to 90% positive, also being the most persistent over 
time. The beta cell function in early DM1 in childhood and adolescence is severely 
compromised since diagnosis, a difference in LADA in that the deficit is less severe. 
It has also been found that there is a correlation between age of diagnosis and fasting 
C-peptide levels, which is related to the latest age of LADA. To explain the later and 
less aggressive presentation compared to DM1, several theories are postulated, among 
others: intermittent crisis of autoimmune aggression (Figure 10) or greater capacity 
to regenerate beta cells and protection against the apoptotic process.
6.4 Clinical characteristics
Patients with LADA are a heterogeneous group, with antibody titers and body 
mass index (BMI). In general, the appearance of the condition is 35 years later, with 
cases described since the age of 25. Patients with LADA tend to have a BMI higher 
than DM1, but less than DM2. The existence of other autoimmune comorbidity or 
their family history is common, mainly thyroid disease. A higher frequency of anti-
peroxidase antibodies (TPO) has been seen, in up to 27% of patients, compared to 
those with anti-GAD negative, which makes it necessary to monitor thyroid func-
tion and perform screening for other autoimmune diseases. The initial response to 
oral therapy is satisfactory, progressing in varying degrees to insulin requirements, 
from 6 months to several years, depending mainly on antibody titers (Table 5). 
Figure 10. 
The destruction of beta cell and the appearance of DM1 according to the age of onset and the putative 
pathogenetic mechanisms.
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High titers of anti-GAD compared to low ones, have lower BMI, less endogenous 
insulin secretion, and faster progression to insulin-dependence. The presence of 
anti-GAD antibodies (or ICA) may be useful to identify patients with a previous 
diagnosis of DM2, who respond partially to treatment with oral antidiabetics and 
who quickly require insulin therapy. Regarding the metabolic profile, patients 
with LADA have advantages regarding DM2 with a better profile, that is, lower 
triglyceride levels, higher levels of HDL, lower BMI, and lower waist circumference. 
There are no specific guidelines for the treatment of patients with LADA. However, 
the metabolic goals are the same as for DM1 and DM2 patients, so you should try to 
achieve HbA1c <7%. The diet and exercise recommendations do not show differ-
ences with the classic presentations. Despite the extensive use of oral antidiabetics 
in DM2, especially metformin, there are no studies of this drug in patients with 
LADA. Glibenclamide and insulin were compared in LADA patients, finding that 
the group that used GBC had worse metabolic control and faster deterioration of CP 
secretion at a follow-up of 30 months. Therefore, the use of sulfonylureas as a first-
line drug in this type of diabetes is not recommended. TZD combined with insulin 
show preservation of beta cell function in a small group of Chinese patients. The 
use of other agents such as insulin sensitizers could be used in combination with 
insulin in patients who share characteristics with DM2, that is, BMI >30 kg/m2 and 
signs of insulin resistance. The role of the iDPP4 is not established. Patients with 
LADA treated with insulin glargine, the effect of adding sitagliptin or placebo was 
compared, the group with sitagliptin had a minimal decrease in C-peptide at one-
year follow-up, compared to placebo. However, more studies support this evidence. 
We should keep in mind, like DM1 and DM2, patients.
Today, evidence indicates that early insulin therapy, along with changes in 
lifestyle, is the therapy of choice in patients with LADA when metabolic control 
is impaired primarily in young patients with elevated antibody titers since this 
treatment slows the deterioration of beta cell function, controls hyperglycemia, and 
prevents glucotoxicity [34]. TZD combined with insulin shows preservation of beta 
cell function in a small group of Chinese patients. The use of other agents such as 
insulin sensitizers could be used in combination with insulin in patients who share 
Clinical features DM1 LADA DM2
Age at diagnosis Childhood and 
adolescence rare 
adulthood
>30 years Adulthood, rare childhood, 
and adolescence
Start Acute Rare acute Slow
Autoimmunity Greatly increased Increased No modifications
Ketosis Frequently Rare Rare
Insulin resistance No modifications Increased or 
without changes
Severely increased
Beta cell function Very reduced Reduced Increased or unchanged
Insulin 
requirements
From the diagnostic >6 months from 
the diagnostic
Years from the diagnostic
Body mass index Low or normal Normal or 
overweight
Overweight or obesity
MHC susceptibility Severely increased Increased No changes
Adapted to [35].
Table 5. 
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characteristics with DM2, that is, BMI >30 kg/m2 and signs of insulin resistance. 
The role of the iDPP4 is not established. Patients with LADA treated with insulin 
glargine, the effect of adding sitagliptin or placebo was compared, the group with 
sitagliptin had a minimal decrease in C-peptide at one-year follow-up, compared to 
placebo. However, more studies support this evidence. We should keep in mind, like 
DM1 and DM2, patients with LADA require a multidisciplinary approach to proper 
treatment.
6.5 Clinical features of DM1, LADA, and DM2
This Table summarizes major clinical features of DM1, LADA, and DM2.
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